[Warrant Insights] Ali Health stands firmly above multiple moving averages showing strong momentum. How to seize the future opportunities?

January 13th [Bank of China Guest] Hang Seng Index, Zijin Mining, Jiangxi Copper, CSPC Pharma, Wuxi Bio, China Life

The performance was quite remarkable! The stock price surged to a high of 7.91 yuan, closing at 7.78 yuan for the day, marking an impressive 18.96% increase. The trading volume reached 7.45 billion yuan, with noticeable expansion in trading activity. Compared to previous periods, the rise in price accompanied by high trading volume is actually a positive sign that could potentially drive the stock price even higher.We 【HK Stock Report】January 14 [HK Stocks Podcast] Hang Seng Index, Tencent, Xiaomi, Wuxi Bio, Trip.Com, Ali Health There's some commentary on Ali Health: Looking back at the past few trading days, Ali Health had been steadily climbing, with only a sharp rise occurring on the last day (the 14th). $Hang Seng Index (800000.HK)$$TENCENT (00700.HK)$$XIAOMI-W (01810.HK)$$WUXI BIO (02269.HK)$$TRIP.COM-S (09961.HK)$

As of 10:25 AM today (15th), Ali Health's latest price was 7.15 yuan, with a temporary pullback of 7.97%,Support levels are at 6.3 yuan and 6.01 yuan respectively, while resistance levels are seen at 8.98 yuan and 9.55 yuan. MA10, MA30, and MA60 are positioned at 5.86 yuan, 5.48 yuan, and 5.66 yuan respectively, with the current stock price clearly standing above all moving averages, presenting a strong trend.In terms of indicators, the RSI is at 82, which is in the overbought zone but shows a neutral stance between buying and selling; MACD, ADX, and several other indicators are signaling a buy. However, the overall technical indicator summary suggests a 'sell' signal with a strength of 9. Among the multiple oscillation indicators, the CCI indicator also signals a buy, indicating some divergence across indicators.

Looking at the warrant market performance, warrants that previously followed the underlying stock's trend have shown strong elasticity. Reviewing the two Ali Health call warrants selected on January 12, 2026, both recorded significant gains: $CTALIHI@EC2605A.C (18253.HK)$ The increase reached 106% after two days, $HUALIHI@EC2606A.C (17380.HK)$ with one warrant’s increase reaching as high as 117% after two days, compared to the underlying stock’s rise of 22.33% during the same period. It is evident that the strong upward movement of the underlying stock significantly amplified the elasticity of the call warrants, fully reflecting the leverage effect of warrants.

Considering the current trend of Ali Health and the status of the warrant pool, two high cost-performance call warrants have been carefully selected for your reference.

The first one is $SGALIHI@EC2606A.C (23068.HK)$ , with an exercise price of 8.61 yuan and a leverage of 3.6 times. Its core advantage lies in having relatively ideal leverage and implied volatility, ensuring sufficient room for elasticity while controlling additional costs caused by fluctuations in implied volatility, making it suitable for strategies requiring elasticity and risk balance.

The second is $HUALIHI@EC2606B.C (20196.HK)$ , with an exercise price of 8.6 yuan and a leverage of 3.7 times. The standout feature of this product is its premium and implied volatility, which are the lowest among similar products, offering clear cost-efficiency advantages. It is more attractive to investors seeking low-cost deployment and focusing on long-term value, and both products have good liquidity to support normal trading operations.

Risk Warning:It should be noted that the RSI for Ali Health is currently in the overbought zone. Although the short-term trend is strong, there is still the possibility of a short-term pullback. Investors in related call warrants should be cautious about warrant price fluctuations due to pullbacks in the underlying stock. Additionally, both selected call warrants are slightly out-of-the-money products. If the underlying stock fails to continue rising and break through resistance levels, time decay will gradually increase as the remaining term decreases. Long-term holding is not recommended, and close tracking of the underlying stock’s movements and technical indicator changes is needed to adjust strategies in a timely manner.

Ali Health's technicals show buy signals across multiple indicators, but the RSI is overbought. Would you choose the Societe Generale call warrant (23068) with better leverage to capture elasticity, or opt for the Huatai call warrant (20196) with lower premiums for a low-cost strategy? Share your thoughts in the comments.! Want more analysis? Don't forget to follow 'HK Stock Warrants Jenny' for daily updates!

Disclaimer: This article does not constitute any investment advice.

This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We shall not be liable for any loss or damage arising from reliance on the information in this article. Technical analysis merely indicates whether certain technical conditions are met; a comprehensive evaluation of asset performance should incorporate additional data. Trading decisions should not be based solely on the content of this article. Please note that past performance is not indicative of future results.

#Ali Health #Hong Kong Stocks #Real-time Analysis #Warrants Selection #Warrants Strategy #Derivatives Hedging #Hong Kong Stock Warrants Jenny #Ali Health #Pharmaceutical Stocks #Technical Analysis

99K Views